Our Mission and Vision

Arming the patient’s immune system to fight cancer

Targovax’s team of dedicated, high calibre individuals have brought this company to where it is today, but to drive its success further, we are looking for talented and high performing individuals.

Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapies for cancer patients based on two proprietary technology platforms: oncolytic viruses and peptide vaccines. The drug candidates are designed to program the immune system to better target, attack and kill cancer cells in the patient. Targovax is currently running three and starting three clinical trials, combining its drug candidates with immune checkpoint inhibitors and standard of care.

Targovax is a Nordic leader in the immuno-oncology field born out of the merger on 2 July 2015 of Targovax of Norway and Oncos Therapeutics of Finland. Targovax was listed on the Oslo Stock Exchange July 2016 and has offices in Oslo and Helsinki.

We don’t have any open positions at the moment, but if you would like to send us an open application we will keep your records on file. Please send it to contact@targovax.com.